EASL European Association for the study of the Liver
2
Obesity epidemic results in Non-Alcoholic Fatty Liver Disease (NAFLD) becoming the most common cause of liver disease in Europe
plus
Actualités sur Medizin, Gesundheit
OrbusNeich® Announces Japan Approval for COMBO® Plus Coronary Stent
Hong Kong (ots/PRNewswire) - OrbusNeich Medical K.K. of Tokyo Japan has announced that the Japan Ministry of Health, Labour, and Welfare (MHLW) has granted Shonin market approval for the COMBO Plus Coronary Stent. The COMBO Plus Coronary Stent is the first drug-eluting stent [DES] to combine the proprietary endothelial progenitor cell [EPC] capture technology with an ...
plusEthicon Launches New Powered Circular Stapler With Dual Technologies to Reduce Anastomotic Complications in Colorectal, Gastric, and Thoracic Surgery
Innovative technology helps address critical challenge of anastomotic leaks which can occur in up to 8.6% of colorectal surgeries1,11% in oesophagectomies2 and 4% in gastrectomies3 Vienna (ots/PRNewswire) - Ethicon*, part of the Johnson & Johnson Medical Devices Companies**, today announced the launch of the ...
plusNew Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care
Not intended for distribution in the USA, Canada or the UK Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: 4062; 4934. - New subgroup analyses for ...
plusExperts Consider Osteoporosis to Be a Silent Epidemic Which Is Neglected and Under Addressed, According to New Survey Released Today
- Osteoporosis is estimated to affect 200 million people worldwide1 and results in a fracture every 3 seconds2 yet a new survey reveals bone specialists in Europe think its impact is not fully recognised3 - Specialists (82%) believe osteoporosis is a silent epidemic, yet only 24% believe their healthcare system is ...
plusHovione Announces Successful End-of-phase 2 Meeting With the FDA and Outlines Phase 3 Program for Minocycline Topical Gel
Cork, Ireland (ots/PRNewswire) - Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea. At a recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), Hovione ...
plus
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Not intended for US, Canada and UK-based media - Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission anticipated in fourth quarter of 2019 Darmstadt, Germany and ...
plusSOPHiA GENETICS Expands Executive Team With a Chief Marketing Officer and New Chief Information Officer
Lausanne, Switzerland, and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Gaëtan Fraikin and Sergei Yakneen have joined its executive team as Chief Marketing Officer and Chief Information Officer, respectively. Mr. Fraikin and Mr. Yakneen bring decades of highly ...
plusFor the First Time Ever, Fans Can Go Behind the Scenes During Pre-season at FC Barcelona, Thanks to New Exclusive 4-part Series by Beko
Exclusive digital series shines a light on the staff that work diligently at Ciutat Esportiva to make a healthier lifestyle possible for the FC Barcelona first team Istanbul (ots/PRNewswire) - Today, Beko, the leading home appliance brand in Europe, in partnership with FC Barcelona, will premiere "Pros Behind The ...
plusTresiba® Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes
Barcelona, Spain (ots/PRNewswire) - According to new data from the CONCLUDE head-to-head trial, Tresiba® (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in adults with type 2 diabetes ...
plusUnited Nations Political Declaration on Universal Health Coverage finally has some teeth / Oral health included in global health agenda
Geneva, Switzerland (ots) - FDI World Dental Federation (FDI) welcomes the long overdue commitment to strengthening oral health in the UN Political Declaration on Universal Health Coverage (UHC) (http://ots.ch/juoOII). The declaration will be officially adopted by world leaders at the UN High-Level Meeting on UHC on ...
plusSenzer's Medical Device Approved in Europe for the Safe and Effective Delivery of Cannabinoids
London (ots/PRNewswire) - Senzer Pharmaceuticals has been granted a CE Mark that certifies its inhaler as a medical device, allowing it to now be available for patients in Europe for the 'safe and effective delivery of pharmaceutical cannabinoids.' The Class IIa Medical Device approval is the first-ever in the cannabinoid space and clears the way for the UK-based ...
plus
Ozempic® Offers Superior Reductions in HbA1c and Body Weight Compared to Both Victoza® and Canagliflozin in People With Type 2 Diabetes
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk announced today the results from two Ozempic® (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed: - Ozempic® was superior to treatment with the SGLT-2 inhibitor canagliflozin (300 mg) in reducing HbA1c and ...
plusOral semaglutide improves glycaemic control in people with type 2 diabetes across baseline blood sugar levels
Barcelona, Spain (ots/PRNewswire) - Novo Nordisk today announced findings from an exploratory analysis of the PIONEER trial programme, showing oral semaglutide (3, 7 and 14 mg) improved glycaemic control in people with type 2 diabetes across baseline HbA1c levels. Greater reductions in HbA1c were demonstrated with 7 ...
plusFiasp® Demonstrated Effective Overall Blood Sugar Reductions in People With Advanced Type 2 Diabetes Uncontrolled on Multiple Daily Injections (Basal-bolus Regimen)
Bagsværd, Denmark (ots/PRNewswire) - New data presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with advanced type 2 diabetes (>=10 years of diagnosis) not optimally controlled on their current basal-bolus regimen, Fiasp® (fast-acting ...
plusSanten Makes Waves at ESCRS 2019 With Significant Expansion Into Surgical Devices and Publication of Real-world Evidence in Dry Eye Disease
Geneva (ots/PRNewswire) - Santen EMEA's significant expansion into the surgical devices arena is underlined by the company's activities at this year's European Society of Cataract and Refractive Surgeons (ESCRS) congress. In addition to the launch of a new monofocal, hydrophobic intraocular lens (IOL), xact(TM) ...
plusSofWave Medical's Low-Divergence Ultrasound Technology Has Received FDA Clearance for the Aesthetic Treatment of Facial Lines and Wrinkles
Yoqneam, Israel (ots/PRNewswire) - Sofwave Medical Ltd., an emerging aesthetic device company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Sofwave system. The Sofwave device is indicated for use as a non-invasive aesthetic treatment to improve facial lines ...
plusHelsana report shows: Medical services on the rise
Zürich (ots) - The "Volume Report" published today by Helsana elucidates the development of medical treatments. In Switzerland, increasing numbers of patients make use of medical treatments. As a result there is an increased need for coordination. General practitioners have less and less time to perform this role. The report finds great potential to meet these coordination needs in other health occupations. In its latest ...
plus
Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis - The designation is based on data from the ...
plusZentiva Enhances its Global Manufacturing Footprint by Signing an Agreement to Acquire Manufacturing Site in Ankleshwar, India
Prague, Mumbai and Ankleshwar, India (ots/PRNewswire) - Zentiva Group, a.s. announces the signing of a Business Transfer Agreement with Sanofi to acquire their manufacturing site in Ankleshwar, India. This acquisition will help ensure the continued supply of high-quality medicines to more patients by expanding the ...
plusUpdated Results for Investigational Therapy Tepotinib Presented at WCLC 2019
- Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation and select MET dysregulations The information contained is not intended for ...
plusEW Nutrition, awarded the 2019 Outstanding Contribution Award for reducing antibiotic resistance in the layer industry
plusNewly Published ROSacea COnsensus (ROSCO) Expert Recommendations Encourage Dermatologists to Upweight Burden-related Discussions, Aim For 'Complete Clearance' of Symptoms and Consider Combination Therapy For Severe Patients
Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Lausanne, Switzerland (ots/PRNewswire) - Published online in the British Journal of ...
plusSpePharm AG Wins Case Against Eisai Inc. in United States District Court for District of Delaware
Amsterdam (ots/PRNewswire) - SpePharm AG, a subsidiary of Norgine B.V., announced that the United States District Court for the District of Delaware ruled on 4th September 2019 in favour of SpePharm in its proceeding against Eisai Inc., upholding SpePharm's licensed rights for SALAGEN® (pilocarpine hydrochloride) ...
plus
FDI World Dental Federation and Smile Train launch project to improve oral health of children with clefts: the most common birth difference of the face and mouth
plusHarvestFresh by Beko Mimics Sunlight in Order to Preserve Vitamins for Longer* and Keep Fruits and Vegetables as Fresh as the Day They Were Picked
HarvestFresh harnesses innovative illumination technology to maintain vitamins in fresh produce Berlin (ots/PRNewswire) - What if fruits and vegetables could remain as nutritious stored in the refrigerator as the day we bought them? Now, thanks to cutting edge technology from Beko, Europe's leading home appliances ...
plus- 2
New FDI World Dental Federation care pathway promotes dentist-patient collaboration to manage partial tooth loss
plus Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial Fibrillation
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - Data contributes to growing body of ...
plusDebiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients
Lausanne, Switzerland (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced positive topline results across clinical endpoints following the completion of the two-year follow-up period of its double-blind, randomized Phase II study of Debio 1143 in high-risk, previously untreated ...
plusETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in Elderly NVAF Patients
- Global and European real-world outcome analyses in non-selected atrial fibrillation (AF) patients on edoxaban, including those who are elderly with comorbidities, were reported at ESC Congress 2019 - At present, the Global ETNA-AF programme is the largest and most comprehensive repository of routine clinical ...
plus
Précédent23242526272829303132Suivant